CG Oncology has announced that topline data from its Phase 3 PIVOT-006 trial of intravesical cretostimogene grenadenorepvec ...

The number and frequency of intravesical instillations for non-muscle-invasive bladder cancer (NMIBC) impairs quality of life and needs to be reported in clinical trials.

Pfizer Inc. (NYSE:PFE) is one of the most buzzing stocks to invest in according to hedge funds. Earlier on December 17, ...

For individuals facing fear, uncertainty and repeated procedures associated with recurrent low-grade intermediate-risk bladder tumors, timely access to treatment can be critical. ZUSDURI, the first ...

PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy for intermediate-risk NMIBC now expected in 1H 2026, nearly one year ahead ...

Padcev is approved for use in combination with the programmed death 1 inhibitor Keytruda (pembrolizumab) or Keytruda QLEX (pembrolizumab and berahyaluronidase alfa-pmph) as neoadjuvant treatment and ...

An update from the phase 2 LEGEND trial shows that the investigational nonviral gene therapy detalimogene voraplasmid has achieved a 62% complete response rate at six months in patients with high-risk ...

When it comes to bladder cancer, it’s important to note the differences between muscle-invasive and non-muscle-invasive bladder cancer, as it can affect the staging of the cancer. The “stage” (spread) ...

Merck’s Keytruda is riding a winning streak in bladder cancer. Following FDA approvals in the metastatic and non-muscle invasive settings, the anti-PD-1 therapy has delivered a positive readout in ...

Senior male patient in hospital gown seen through CAT scan machine. Male patient at clinic for MRI scan. The 2023 guideline on managing muscle-invasive bladder cancer offers evidence-based ...

New research presented at the 2025 International Kidney Cancer Symposium found that patients with localized renal cell ...